Accordingly, therapeutic strategies for the treatment of diabetes aim to improve insulin sensitivity (thiazolidinediones) or augment insulin secretion from the pancreatic β-cell (sulphonylurea receptor inhibitors). This evidence concerns the gene INS and diabetes mellitus.